Connect with us

Health

Europe’s last end-to-end antibiotics maker says it’s at ‘breaking point’

SHARE:

Published

3 weeks ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

Sandoz, which operates Europe’s last major end-to-end antibiotics manufacturing chain at its Kundl plant in Austria, has warned that below-cost imports from China of the active pharmaceutical ingredients (APIs) used to produce amoxicillin are threatening the EU’s capacity to manufacture essential medicines.

In a statement to Vital Signs, Sandoz said it had filed a draft anti-dumping complaint with the European Commission because the situation had reached "breaking point", due to sustained below-cost pricing and clear market distortions putting Europe’s last major antibiotic manufacturer at risk.

The company says the complaint contains evidence of practices that appear to be incompatible with “fair, rules-based international trade”.

“Sandoz is not seeking.... 

Share this article:

Share this:
Related Topics:
Guest Contributor - Opinion

Opinions expressed are purely those of the author and not endorsed by EU Reporter. The article was unsolicited by EU Reporter, and the author guarantees the truthfulness of the contents of the article. No payment was made by EU Reporter to the author

EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending